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Aim: Ultrasound protocols to measure carotid intima media thickness (CIMT) differ considerably 
with regard to the inclusion of the number of carotid segments and angles used. Detailed information 
on the completeness of CIMT information is often lacking in published reports, and at most, overall 
percentages are presented. We therefore decided to study the completeness of CIMT measurements 
and its relation with vascular risk factors using data from two CIMT intervention studies: one among 
familial hypercholesterolemia (FH) patients, the Rating Atherosclerotic Disease change by Imaging 
With A New CETP Inhibitor (RADIANCE 1), and one among mixed dyslipidemia (MD) patients, 
the Rating Atherosclerotic Disease change by Imaging With A New CETP Inhibitor (RADIANCE 2).
Methods: We used baseline ultrasound scans from the RADIANCE 1 (n=872) and RADIANCE 2 
(n=752) studies. CIMT images were recorded for 12 artery-wall combinations (near and far walls of 
the left and right common carotid artery (CCA), bifurcation (BIF) and internal carotid artery (ICA) 
segments) at 4 set angles, resulting in 48 possible measurements per patient. The presence or absence 
of CIMT measurements was assessed per artery-wall combination and per angle. The relation 
between completeness and patient characteristics was evaluated with logistic regression analysis.
Results: In 89% of the FH patients, information on CIMT could be obtained on all twelve carotid 
segments, and in 7.6%, eleven segments had CIMT information (nearly complete 96.6%). For MD 
patients this was 74.6% and 17.9%, respectively (nearly complete: 92.5%). Increased body mass 
index and increased waist circumference were significantly (p=0.01) related to less complete data in 
FH patients. For MD patients, relations were seen with increased waist circumference (p＜0.01). 
Segment-specific data indicated that in FH patients, completeness was less for the near wall of the 
left (96%) and right internal carotid artery (94%) as compared to other segments (all ＞98%). In 
MD patients, completeness was lower for the near wall of both the right and left carotid arteries: 
86.0% and 90.8%, respectively, as compared to other segments (all ＞97%).
Conclusions: With the current ultrasound protocols it is possible to obtain a very high level of com-
pleteness. Apart from the population studied, body mass index and waist circumference are impor-
tant in achieving complete CIMT measurements.
J Atheroscler Thromb, 2010; 17:526-535.
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Introduction
Carotid intima-media thickness (CIMT) mea-
surements have been used widely to evaluate cardio-
vascular disease (CVD) risk factors and CVD morbid-
ity and mortality1-3). Changes in CIMT over time are 
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in which 752 participants with mixed dyslipidemia 
were randomly assigned to atorvastatin monotherapy 
or atorvastatin combined with 60 mg torcetrapib for 2 
years to assess the effect of torcetrapib on the progres-
sion of atherosclerosis.
Carotid Ultrasound Examinations
The ultrasound protocol for assessment of CIMT 
has been described in detail elsewhere11, 12, 20, 21). In 
short, duplicate scans were made at baseline and at 
each patient’s final visit, and single scans at visits at 6, 
12, and 18 months, to give a maximum of seven scans 
for each patient. At each visit, sonographers acquired 
and recorded CIMT images of 12 artery-wall combi-
nations of the near and far walls of the right and left 
carotid artery for the common, bifurcation, and inter-
nal carotid artery segments, at four predefined angles 
of 30° steps (90° to 180° on the right side and 270° 
to 180° on the left side) using the Meijers Carotid 
Arc©. This resulted in 48 possible measurements per 
patient. All imaging centers used the same imaging 
acquisition protocol and equipment (Sequoia 512 
scanners equipped with 8L5 transducers; Siemens 
AG, Munich, Germany). Forty-eight 5-second image 
sequences (video clips) were saved in DICOM format 
(Digital Imaging in Communications in Medicine; 
National Electrical Manufacturers Association, Ross-
lyn, VA, USA). Imaging data were transferred directly 
from the study sites to the two reading centers (Vascu-
lar Imaging Center, University Medical Center, Utre-
cht, The Netherlands, and Wake Forest University 
Medical Center, Ultrasound Reading Center, Win-
ston-Salem, NC, USA), where standardized equipment 
and protocols were used to process stored images. 
From every image sequence, readers selected one frame 
in end diastole for measurement of CIMT. Maximum 
thickness (and also mean of the common carotid 
artery) was measured semi-automatically with Artery 
Measurement System software (Chalmers University, 
Göthenburg, Sweden)20). A ‘no measurement’ could 
have resulted from two processes: (1) no imaging data 
had been stored for that specific angle and segment, or 
(2) the data provided were of insufficient quality to 
perform a CIMT measurement, as judged by the 
reader. Unfortunately, we were not able to distinguish 
between the two processes and additional information 
on whether a ‘no measurement’ was due to, for exam-
ple, tortuous vessels, extreme acoustic shadowing, 
reverberations or artifacts was unfortunately not col-
lected. Readers were unaware of the interventions 
assigned to patients, and of previous measurements. 
Quality assurance protocols have been described else-
where18). In short, quality assurance processes included 
being used to measure the efficacy of pharmacological 
interventions where CIMT is used as an alternative 
marker for atherosclerotic vascular disease risk4-14). At 
present, there is little agreement on ultrasound proto-
cols to measure CIMT and they vary in measuring 
single or double walls (near and/or far wall), or single 
or multiple segments at set / pre specified angle(s) or 
unspecified free angle(s).
Completeness of CIMT information is often one 
of the arguments to restrict protocols to imaging the 
far wall of the common carotid artery only, or to 
imaging of the far wall of the other segments. Pub-
lished data on the completeness of CIMT information 
stems from observational studies performed in the 
early nineties, when the yield of imaging of the bifur-
cation segment and internal carotid artery segment 
was limited15-19). Ultrasound protocols and imaging 
equipment have changed considerably, and ultrasound 
protocols for trials are generally more standardized 
than in earlier observational CIMT studies. Thus, these 
early estimates may not be applicable to the current 
situation. Furthermore, from the published informa-
tion, in recent trials, aspects of the completeness of 
carotid segments and walls seem not to be available. If 
anything, generally, overall completeness information 
is presented7, 9, 11-14). In addition, information on fac-
tors that reduce the completeness of CIMT measure-
ment assessment has not been widely addressed in the 
literature; however, from experience, it is well known 
that carotid ultrasound imaging is more difficult in 
subjects with a short and thick neck.
In view of the lack of published information on 
these issues, we set out to study this using a large body 
of data obtained in two recently performed random-
ized controlled trials.
Methods
General
Data from the RADIANCE 112, 18) and RADI-
ANCE 2 trials were used11, 18). The current analyses 
are based on participants that had at least one post-
baseline CIMT measurement. These studies have been 
described in detail previously. In summary, RADI-
ANCE 1 was a double-blind randomized placebo-
controlled multi-center study in which 872 patients 
with heterozygous familial hypercholesterolemia (FH) 
were randomly assigned to receive either atorvastatin 
monotherapy or atorvastatin combined with 60 mg 
torcetrapib, a cholesteryl ester transfer protein (CETP) 
inhibitor, for 2 years to study the effect on CIMT pro-
gression. RADIANCE 2 was a comparative study, a 
double-blind, placebo-controlled multi-center study 
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the following: central training and certification of all 
sonographers and readers on each continent; annual 
international meetings of sonographers and readers to 
reinforce protocol and standardize implementation; 
and regular site visits and performance reviews. This 
included consensus among readers in deciding when a 
CIMT measurement could not be taken.
Statistical Methods
Completeness, defined as the presence of a CIMT 
measurement, was addressed in various ways since 
information on CIMT availability was present on an 
angle level (4 angles), wall level (near and far wall), 
carotid segment level (CCA, BIF, ICA), carotid side 
level (left, right) and overall (2×3×2=12 artery-wall 
combinations). Furthermore, when the study interest 
lies in the measurement of mean maximum CIMT, 
information of CIMT in the twelve segments should 
be available, and thus completeness of 12 artery-wall 
combinations was studied separately.
First, completeness was presented by angle and 
carotid segment separately. Next, the availability of 
one or more angle-specific CIMT measurements per 
carotid segment was presented. Subsequently, data 
were given for certain angle specific combinations by 
segment. Finally, the completeness of CIMT was pre-
sented by segments (complete was defined as CIMT 
available for all 12 artery-wall combinations).
The relation of completeness, i.e., CIMT avail-
able for all 12 segments, with several vascular risk fac-
tors, was studied using a logistic regression model. 
The outcome ‘complete’ was defined as CIMT avail-
able for all 12 segments. The odds ratio (OR) and its 
corresponding 95% confidence interval (95%CI) were 
estimated for several risk factors. An increased odds 
ratio (＞1) should be interpreted as an increased risk 
of obtaining incomplete data. Results are presented 
for the two RADIANCE studies separately. Data were 
analyzed using SPSS version 14.0.
Results
Baseline characteristics of the study populations 
are given in Table 1. Participants in the RADIANCE 
1 study were younger, had higher levels of LDL cho-
lesterol, lower levels of triglycerides, lower waist cir-
cumference values and lower body mass index than 
participants in the RADIANCE 2 study (Table 1). 
There were more male participants and hypertension 
was less common in RADIANCE 2 than RADIANCE 
1. Furthermore, CIMT was considerably higher in MD 
patients than FH patients.
Completeness per Segment
The availability of at least 1 CIMT measurement 
(out of the 4 (angles)) was 93.7% in the FH patient 
trial and 86.0% in the MD patient trial (Fig.1). Seg-
ment-specific data indicated that, in FH patients, 
completeness was somewhat less for the near wall of 
the near and right internal artery (93.7%) than for 
Table 1. Baseline characteristics of the RADIANCE 1 and RADIANCE 2 study
RADIANCE 1
n=872
RADIANCE 2
n=752
Age (years)
Male, n (%)
Mean maximum CIMT (mm)
Mean common CIMT (mm)
Systolic blood pressure (mm. Hg)
Diastolic blood pressure (mm. Hg)
HDL cholesterol (mg/dL)
LDL cholesterol (mg/dL)
Triglycerides (mg/dL)
Waist circumference (cm)
BMI (kg/m2)
Hypertension＊, n (%)
Diabetes mellitus (%)
Baseline glucose (mg/dL)
45 (12.5)
431 (49.4)
1.14 (0.30)
0.72 (0.15)
116 (11)
73 (7)
52 (13)
139 (37)
113 (64)
89 (12)
26.7 (4.4)
230 (26.4)
22 (2.9)
90.2 (17.8)
57 (8.2)
482 (64)
1.31 (0.31)
0.83 (0.15)
120 (11)
74 (7)
47 (11)
100 (20)
183 (80)
100 (13)
30.1 (4.4)
390 (52)
191 (26)
105 (28.5)
Values presented as the mean (standard deviation) or number (percentage); BMI=body mass 
index; CIMT=carotid intima-media thickness; ＊hypertension defined as systolic blood pressure 
＞130 mm Hg or diastolic blood pressure ＞85 mm Hg or use of antihypertensive medication
528 Dogan et al. 529Completeness of CIMT Measurements in Lipid-Lowering Trials
other segments (all ＞98%). In MD patients, com-
pleteness was lower for the near wall of both the right 
and left carotid artery: 86.0% and 90.8%, respectively 
than for other segments (all ＞97%).
When completeness was defined as the availability 
of all four angle CIMT measurements, percentages 
were still considerably high in FH patients (Fig.2, 
left). Completeness percentages in general were higher 
for far wall than near wall measurements. Also, the 
completeness percentages declined when going from 
the common carotid segment to the bifurcation seg-
ment to the internal carotid segment. A similar pat-
tern was seen for completeness rates among MD 
patients, although rates were lower than in FH patients 
(Fig.2, right). Obtaining CIMT information from 
the near walls of the internal carotid segments proved 
to be most difficult.
CIMT Measurements per Segment, Wall and Angle
Table 2 provides information on the percentage 
of participants with CIMT measurements divided by 
segment, wall and angle for both studies. Complete-
ness was higher in FH patients than in MD patients 
for nearly all combinations. The near wall of the inter-
nal carotid artery on both the left and right sides had 
the lowest completeness in both studies. Measure-
ments of the 120°/240° and 150°/210° angles were 
most complete.
In studies focusing on the assessment of mean 
maximum CIMT for each participant, i.e., taking the 
average of the maximum CIMT measurement of each 
of the 12 segments, information on completeness (hav-
ing at least one CIMT measurement per segment) is 
important. At least 89.0% of FH patients had one 
CIMT measurements at 12 segments. In addition, 
96.6% had at least one CIMT measurement in 11 seg-
ments. For MD patients these percentages were 74.6% 
and 92.7%, respectively.
Determinants of Completeness
An increased waist circumference and increased 
body mass index in FH patients were related to a sta-
tistically significant increased risk of incompleteness 
(i.e., CIMT measurement in less than 12 segments): 
OR (95%CI) 1.28 (1.07; 1.54) and 1.92 (1.21; 3.05) 
respectively. Age, lipid levels, blood pressure and 
CIMT at baseline showed no relation with complete-
ness (Table 3). In the MD population, an increased 
Fig.1. Availability of CIMT measurements per standard artery segment
Availability is defined as at least one CIMT measurement at any one of the four angles / measurements of each one of twelve standard artery 
segments. RCN: near wall of the right common carotid artery; RCF: far wall of the right common carotid artery; LCN: near wall of the left 
common carotid artery; LCF: far wall of the left common carotid artery; RBN: near wall of the right bifurcation; RBF: far wall of the right 
bifurcation; LBN: near wall of the left bifurcation; LBF: far wall of the left bifurcation; RIN: near wall of the right internal carotid artery; 
RIF: far wall of the right internal carotid artery; LIN: near wall of the left internal carotid artery; LIF: far wall of the left internal carotid 
artery)
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Fig.2. Availability of CIMT measurements per standard artery segment.
CIMT measurements of 0 (=none) / 1 / 2 / 3 / 4 (all 4 angles) available. RCN: near wall of the right common carotid artery; RCF: far wall of 
the right common carotid artery; LCN: near wall of the left common carotid artery; LCF: far wall of the left common carotid artery; RBN: 
near wall of the right bifurcation; RBF: far wall of the right bifurcation; LBN: near wall of the left bifurcation; LBF: far wall of the left bifur-
cation; RIN: near wall of the right internal carotid artery; RIF: far wall of the right internal carotid artery; LIN: near wall of the left internal 
carotid artery; LIF: far wall of the left internal carotid artery)
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Table 2. Percentage of CIMT measurements presented by wall, segment and angle in RADIANCE 1 (872 scans) and RADIANCE 
2 (752 scans) at baseline
RADIANCE 1 RADIANCE 2
90° 120° 150° 180° 90° 120° 150° 180°
RCN
RCF
RBN
RBF
RIN
RIF
92,7%
95,3%
90,8%
90,6%
71,4%
84,3%
96,0%
98,2%
90,6%
95,8%
75,0%
92,2%
95,8%
98,5%
85,8%
96,4%
64,0%
91,5%
89,4%
96,8%
78,4%
93,5%
59,4%
88,4%
RCN
RCF
RBN
RBF
RIN
RIF
84,6%
90,3%
76,0%
83,0%
80,7%
82,0%
90,9%
94,9%
89,3%
94,1%
83,9%
90,0%
88,5%
96,0%
87,1%
95,3%
79,0%
91,1%
78,4%
90,9%
79,4%
90,7%
72,2%
87,4%
270° 240° 210° 180° 270° 240° 210° 180°
LCN
LCF
LBN
LBF
LIN
LIF
92,1%
94,0%
84,1%
89,0%
80,4%
80,8%
96,4%
98,5%
90,0%
94,4%
75,6%
89,9%
94,4%
98,2%
82,7%
95,4%
65,0%
92,1%
88,9%
96,3%
79,5%
92,9%
60,9%
88,8%
LCN
LCF
LBN
LBF
LIN
LIF
69,8%
77,9%
62,6%
75,2%
66,2%
71,0%
81,1%
89,3%
62,1%
82,3%
73,5%
83,8%
75,8%
91,3%
56,5%
87,9%
58,6%
87,6%
68,3%
88,5%
48,7%
82,6%
51,1%
84,6%
The right carotid artery is scanned at 90°, 120°, 150° and 180°; the left artery scanned at equivalent angles 270°, 240°, 210° and 180°. RCN: near 
wall of the right common carotid artery; RCF: far wall of the right common carotid artery; LCN: near wall of the left common carotid artery; LCF: 
far wall of the left common carotid artery; RBN: near wall of the right bifurcation; RBF: far wall of the right bifurcation; LBN: near wall of the left 
bifurcation; LBF: far wall of the left bifurcation; RIN: near wall of the right internal carotid artery; RIF: far wall of the right internal carotid artery; 
LIN: near wall of the left internal carotid artery; LIF: far wall of the left internal carotid artery)
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body mass index was related to an increased risk of 
incompleteness with an OR (95%CI) 2.04 (1.40; 
2.98). Waist circumference showed the same trend; 
however, this did not reach statistical significance 
(Table 3). Indicators of glucose intolerance (diabetes 
and glucose) were significantly related to lack of com-
pleteness; however, in an analyses in which BMI was 
taken into account, the glucose intolerance relations 
lost statistical significance. P value for diabetes melli-
tus in adjusted models was 0.15 and 0.06 for glucose 
levels, indicating that the relations with glucose intol-
erance is mainly due to body mass index.
Change Over Time in Completeness
To check whether there was change in complete-
ness over time, we repeated these analyses for both 
studies for the duplicate end of study ultrasound scans 
(results not shown). The results were comparable with 
a slight improvement for completeness in all angles 
and artery-wall combination, most probably due to 
the increasing experience of sonographers and readers 
who performed the ultrasound scans. Again, the near 
wall of the internal carotid artery and the extreme 
angle 180° had the lowest level of completeness.
Discussion
The present study provides empirical data on the 
completeness of CIMT using current ultrasound pro-
tocols. We show that the completeness of CIMT mea-
surements is very high, and is related to segments of 
the carotid artery, the wall and the angles at which 
they are examined. Furthermore, increased body mass 
index and waist circumference affects the ability to 
obtain CIMT measurements. Finally, the characteris-
tics of the study population also appear to be an influ-
ence.
There are some methodological issues that need 
to be considered. In the current analyses we recorded 
the presence of CIMT measurement without further 
studying the CIMT values for correctness. Some 
CIMT measurements might have been incorrect and 
thus should have been removed from the dataset and 
thus our completeness rates may be overestimated. 
However, because of the high standard of the core lab-
oratory in which the measurements were performed, 
with periodic quality assessments of intra- and inter-
reader reproducibility, we consider that a material 
effect of inaccurate measurements on our findings is 
unlikely. Furthermore, these were the CIMT measure-
ment on which the original literature11, 12) was based.
Comparison of our findings with other studies is 
difficult, since the literature generally only presents 
overall completeness rates, which to some extent are 
unclear as to what determines the numerator and 
denominator. Overall reported completeness rates 
included 88% in the ENHANCE-study13) and 88.6% 
in the OPAL study21). Specified completeness mea-
sures were provided in the observational Muscatine 
study among young and middle-aged adults22) with 
percentages of complete CIMT measurements at the 
common carotid artery (near wall: 98.9%; far wall: 
Table 3. Relation between vascular risk factors with incompleteness of CIMT measurements. Incompleteness defined as 
less than all CIMT measurement in 12 segments
Unadjusted
RADIANCE 1 RADIANCE 2
OR 95% ci p-value OR 95% ci p-value
Age (years)
Systolic blood pressure (mm. Hg)
Diastolic blood pressure (mm. Hg)
HDL-cholesterol (mg/dL)
LDL-cholesterol (mg/dL)
Triglycerides (mg/dL)
Waist circumference (cm)
Body mass index (kg/m2)
Glucose level (per 10 mg/DL)
History of diabetes mellitus
Mean common CIMT (mm)
Mean maximum CIMT (mm)
1,08
0,97
1,05
0,94
1,00
1,02
1,28
1,92
1.02
1.31
1,34
0,94
(0,91;1,28)
(0,79;1,19)
(0,76;1,44)
(0,80;1,11)
(0,95;1,06)
(0,99;1,05)
(1,07;1,54)
(1,21;3,05)
(0.90;1.14)
(0.38;4.5)
(0,61;2,94)
(0,46;1,90)
0,38
0,75
0,77
0,46
0,95
0,23
0,01
0,01
0.80
0.67
0,47
0,86
0,97
1,08
1,16
0,87
0,98
1,02
1,12
2,04
1.07
1.47
0,61
0,51
(0,80;1,19)
(0,93;1,26)
(0,91;1,48)
(0,74;1,02)
(0,90;1,06)
(0,94;1,11)
(0,98;1,28)
(1,40;2,98)
(1.02;1.13)
(1.02;2.12)
(0,21;1,71)
(0,25;1,05)
0,79
0,31
0,22
0,09
0,57
0,60
0,09
0,00
0.01
0.04
0,34
0,07
OR: odds ratio; 95%CI: 95% confidence interval. Odds ratios represent the odds on completeness of measurements (complete=CIMT 
measurements at all 12 artery segment - wall combinations) with an increase of 10 units of the risk factor, except for mean common 
and mean maximum CIMT
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99.7%), the carotid bifurcation (near wall: 92.7%; far 
wall: 92.8%) and the internal carotid artery (near wall: 
74.0%; far wall: 88.0%). Our overall estimates in 
FH and MD subjects compare favorably with those 
results.
In the RADIANCE studies, sonographers and 
readers were trained and certified before the study. 
Furthermore, continuous quality control measures 
were taken18). Our longitudinal findings suggest that 
the experience of sonographers and readers minimally 
affects the improved measurement availability of seg-
ments and angles, and thus point towards patient 
characteristics as the main source of completeness.
Completeness was lower in the mixed dyslipid-
emia population than the familial hypercholesterol-
emia population, which may be attributed to several 
aspects. First, the MD population was clearly more 
overweight, which is related to more incompleteness 
through either a physical limitation (short, thicker 
neck), which makes image acquisition more difficult, 
or through the fact that the ultrasound appearance of 
the CIMT in the near and far walls in these subjects is 
more difficult to distinguish because of surrounding 
tissues. Secondly, the MD population had a more 
extensive atherosclerosis burden, as indicated by 
thicker common and mean maximum CIMT. It is 
well appreciated that arterial walls are more difficult to 
visualize in the presence of acoustic shadowing, and 
thus a CIMT measurement is more difficult to per-
form. Finally, the way atherosclerosis develops in FH 
patients may be different than in MD patients; the 
former giving rise to more circular homogenous devel-
opment, whereas the latter more heterogenous and 
plaque like23).
In contrast to general opinion (i.e., high lack of 
completeness for bifurcation and internal segments), 
our findings indicate that high levels of completeness 
can be obtained for most artery-wall combinations of 
the carotid artery if multiple measurements are per-
formed per artery-wall combination (multiple angles). 
The question that has not been addressed is whether 
lack of completeness affects the estimated CIMT 
progression rates and affects the direction and magni-
tude of the treatment effect. Presently, several statisti-
cal models exist that can be applied to datasets with 
missing data, e.g. multilevel linear mixed-effects 
model7, 24-26). In this statistical approach, regression 
lines are fitted using restricted maximum likelihood 
methods to site-specific CIMT values rather than to 
means over carotid sites to deal with missing data. The 
reason for this is that some carotid artery sites are con-
sistently more difficult to visualize than others, giving 
rise to missing data, depending on the site. These 
models, using all available CIMT measurement points 
at all visits, provide progression estimates that are less 
biased by lack for completeness. Another approach to 
deal with missing data is imputation27-29). To the best 
of our knowledge, the consequence of imputation on 
CIMT progression estimates and treatment effects has 
not been quantified, although in one study7) the appli-
cation of imputation was described briefly, not affect-
ing the main results. Finally, an approach to limit lack 
of completeness, is to restrict the ultrasound protocol 
to segments, walls and angle that show high complete-
ness levels; however, studies into the effect of such 
choices on reproducibility, CIMT progression esti-
mates and the ability to detect treatment effects are 
very limited30), have only been published in abstract 
form at conferences31), and stem from our group. 
Generally, these analyses indicate that multi-angle pro-
tocols perform ‘better’ in terms of reproducibility 
(higher), progression rates (more precise) and treat-
ment effect (larger and more precise).
In conclusion, with the advanced ultrasound 
technology available today it is possible to obtain a 
high level of completeness in CIMT trials. Apart from 
the type of population studied, body mass index and 
waist circumference are important in achieving com-
plete CIMT measurements.
Trial Registration
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RADIANCE 2 ClinicalTrials.gov number, 
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APPENDIX
Core Laboratories
CIMT Laboratory Europe (C van Everdingen, A 
Geerts, M Geurtsen, M Djuanda, A Kuin, F Leus, R 
Meijer, D Mooiweer-Bogaerdt, K Nijssen, H 
Noordzij, L Romkes, B Sies; E Stooker, F Verhey, B 
van der Vlist, L van der Vlist, E Wineke, H Wisse) 
and at the CIMT Core Laboratory United States (M 
Barr, K Bettermann, S Burton, A Conner-Day, B 
Ettenger, J Griffin, C Halverson, B Holley, L Hoots, J 
Fleshman, M Lauffer, L Passmore, C Sharpe, M 
Wilder, P Miller, T Vitek, G Wolgast).
RADIANCE 1 Investigators
The following investigators are listed according 
to ultrasonography center: Europe: University Medical 
Center Utrecht, Utrecht, the Netherlands– M. Bots 
(co-chair), C. van Everdingen, M. Geurtsen, M. 
Djuanda, A. Kuin, F. Leus, R. Meijer, D. Mooiweer-
Bogaerdt, K. Nijssen (co-chair), H. Noordzij, L. 
Romkes, B. Sies, E. Stooker, F. Verhey, B. van der 
Vlist, L. van der Vlist, E. Wineke, H. Wisse. United 
States: Wake Forest University School of Medicine, 
Winston-Salem, NC – G. Evans and W. Riley (co-
chairs), B. Holley, J. Fleshman, M. Lauffer, L. Pass-
more, M. Wilder, P. Mille, T. Vitek. In addition to the 
authors, the following investigators participated in this 
study: Tygerberg Hospital, Parow, Cape Town, South 
Africa – L. Burgess; Cape Heart Centre University of 
Cape Town Health Science Faculty, Cape Town, South 
Africa – A. Marais; Johannesburg Hospital, Parktown, 
Johannesburg, South Africa – F. Raal; General 
University Hospital, Prague, Czech Republic – R. 
Ceska; Academisch Medisch Centrum, Amsterdam – 
M. Trip; Andro Medical Research, Rotterdam, the 
Netherlands – E. Sijbrands; Clinique des Maladies 
Lipidiques de Québec, Place de la Cité, Quebec, QC, 
Canada – C. Gagne; Vasculair Onderzoek Centrum 
Hoorn, the Netherlands – D. Basart; Academisch 
Ziekenhuis Leiden/Afdeling Inwendige Geneeskunde, 
Leiden, the Netherlands – M. Huisman; Universitair 
Medisch Centrum Utrecht, Utrecht, the Netherlands 
– F. Visseren; University of Utah, Salt Lake City – P. 
Hopkins; TweeSteden Ziekenhuis, Waalwijk, the 
Netherlands – B. Imholz; Universitair Medisch Cen-
trum Sint Radboud, Nijmegen, the Netherlands – A. 
Stalenhoef; Oulu University Hospital, Oys, Finland – 
M. Savolainen; Hartford Hospital, Hartford, CT – P. 
Thompson; Centre de Médecine Génique Commu-
nautaire, Chicoutimi, QC, Canada – D. Gaudet; 
Clinical Research Institute of Montreal, Montreal – J. 
Davignon; University of Kuopio,Research Institute of 
Public Health, Kuopio, Finland – J. Salonen; Univer-
sita degli Studi di Brescia, Brescia, Italy – E. Agabiti 
Rosei; Institute for Clinical and Experimental Medi-
cine, Prague, Czech Republic – R. Cifkova; University 
of Washington, Seattle – R. Knopp; Hôpital de la 
Pitié-Salpetrière,Paris – E. Bruckert; Medisch Cen-
trum Alkmaar, Alkmaar, the Netherlands – J. Sepers; 
Oosterschelde Ziekenhuis, Goes, the Netherlands – A. 
Liem; Andromed Noord, Groningen, the Netherlands 
– J. Jonker; Albert Schweitzer Ziekenhuis, Sliedrecht, 
the Netherlands – A. Cleophas; Health Sciences Cen-
tre, Winnipeg, MB, Canada – D. Mymin; Massachu-
setts General Hospital, Boston – L. Hemphill, R. 
Lees; Baylor College of Medicine, Houston – C. Bal-
lantyne; IRCCS Fondazione C. Mondino, Pavia, Italy 
– A. Cavallini; Reinier de Graaf Gasthuis/Cardio 
Research, Delft, the Netherlands – A. Withagen; Dia-
konessenhuis, Zeist Afdeling Inwendige Geneeskunde, 
Utrecht, the Netherlands – M. Van De Ree; St. Paul’s 
Hospital, Vancouver, BC, Canada – J. Frohlich; 
Columbia-Presbyterian Medical Center, New York – 
H. Ginsberg; University of Minnesota, Minneapolis – 
D. Duprez; and Hopital Jeanne d’Arc Centre d’Inves-
tigation Clinique, Toul, France – B. Guerci.
RADIANCE 2 Investigators
National Clinical Research, Incorporated, Rich-
mond, VA, USA (Hoekstra); Melbourne Internal Med-
icine Associates, Melbourne, FL, USA (R Vicari); Bay-
lor College of Medicine, Houston, TX, USA (C Bal-
lantyne) University of Utah, Cardiovascular Genetics 
Research Clinic, Salt Lake City, UT, USA (P Hop-
kins); Sterling Research Group Limited, Cincinnati, 
OH, USA (E Roth); Benchmark Clinical Manage-
ment Group, Vero Beach, FL, USA (L Hendley); 
CAPRI, Los Angeles, CA, USA (R Davidson); Hart-
ford Hospital, Hartford, CT, USA (P Thompson); 
Saint Luke’s Lipid and Diabetes Research Center, 
Kansas City, MO, USA (A Forker); Institute for Clini-
cal and Experimental Medicine, Prague, Czech Repub-
lic (R Cifkova); Health Sciences Centre, Winnipeg, 
Canada (D Mymin); Centre de santé et de services 
sociaux de Chicoutimi, Chicoutimi, Québec, Canada 
(D Gaudet); Piedmont Medical Research Associates, 
Winston-Salem, NC, USA (T Littlejohn); University 
of Kuopio, Kuopio, Finland (J Salonen); Radiant 
Research, Minneapolis, Edina, MN, USA (J Zavoral); 
Andro Medical Research b.v., Rotterdam, Netherlands 
(E Sijbrands); The University of Texas Health Science 
Center at San Antonio, San Antonio, TX, USA (S 
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Haff ner); Rainier Clinical Research Center, Inc., 
Renton, WA, USA (L Klaff ); St Paul’s Hospital, Van-
couver, BC, Canada (J Frohlich); University of Wash-
ington, Department of Medicine, Northwest Lipid 
Research Clinic, Seattle, WA USA (R Knopp); Diabe-
tes and Glandular Disease Research Associates PA, San 
Antonio, TX, USA (S Schwartz); Horizon Clinical 
Research Associates, PLLC, Gilbert, AZ, USA (V 
Wiener); Hampton Roads Center for Clinical 
Research, Norfolk, VA, USA (B Lubin); University of 
Minnesota, Minneapolis, MN, USA (D Duprez); 
Wake Forest University School of Medicine, Winston-
Salem, NC, USA (J Crouse); Duke General Internal 
Medicine, Durham, NC, USA (E Lausier); Scottsdale 
Cardiovascular Research Institute, Scottsdale, AZ, 
USA (K Vijayaraghavan); Buffalo Cardiology and Pul-
monary Associates, PC, Williamsville, NY, USA (J 
Corbelli); Benchmark Clinical Management Group, 
Inc., Vero Beach, FL, USA (T Sigman); Julius Cen-
trum Utrecht, Utrecht, Netherlands (A Bak); Clinical 
Research Institute of Montreal, Montreal, Québec, 
Canada (J Davignon); Radiant Research Kansas City, 
Overland Park, KS, USA (M Pierson); Salem Research 
Group, Winston-Salem, NC, USA (R Rosen); Radi-
ant Research, Stuart, FL, USA (D Fiske); Covance 
CRU, Inc, San Diego, CA, USA (L Sherman); Diabe-
tes, Endocrine and Internal Medicine Associates, 
Richmond, VA, USA (J Wigand); The Lakeshore 
Clinic, Kirkland, WA, USA (J Cameron); College 
Park Family Care Center, Overland Park, KS, USA 
(D Dobratz); Clinique des maladies Lipidiques de 
Québec, Québec, Canada (C Gagne); Duke University 
Medical Center, Durham, NC, USA (J Guyton); 
University of California, San Diego, La Jolla, CA, 
USA (M Allison); Health Research of Hampton 
Roads, Inc, Newport News, VA, USA (C Fisher); Offi 
ce of Brook Nevins, MD, Bronxville, NY, USA (B 
Nevins); UCLA School of Medicine, Los Angeles, CA, 
USA (M Saad); Cardiology Group of Western New 
York PC, Williamsville, NY, USA (S Calandra); Heart 
& Vascular Institute of Texas, San Antonio, TX, USA 
(J Seaworth); Duke University Medical Center, Dur-
ham, NC, USA (W Kraus); Massachusetts General 
Hospital, Boston, MA, USA (L Hemphill); McGuire 
VA Medical Center, Richmond, VA, USA (F Zieve); 
Comprehensive Cardiology Consultants, Cincinnati, 
OH, USA (D Suresh); Veteran’s Affairs Medical Cen-
ter, Cincinnati, OH, USA (S Khoury); Concord Hos-
pital, Cholesterol Treatment Center, Concord, NH, 
USA (M McGowan); Radiant Research, San Diego 
North, Encinitas, CA, USA (W Pleskow); Universitair 
Medisch Centrum Sint Radboud Internal Medicine, 
Nijmegen, Netherlands (A Stalenhoef ); Carl T 
Hayden Veterans Aff airs Medical Center, Phoenix, 
AZ, USA (J Felicetta); Duke University Medical Cen-
ter, Durham, NC, USA (M Blazing); Cardiovascular 
Research Associates, Boston, MA, USA (E Schaefer); 
Wake Heart Research, Raleigh, NC, USA (J Mann); 
The Rogosin Institute. New York, NY, USA (B Gor-
don); Baylor College of Medicine, Lipid Research 
Clinic, Houston, TX, USA (W Insull); OMNI 
Healthcare PA, Melbourne, FL, USA (M Mendolla); 
University of Texas Health Science Center, San Anto-
nio, San Antonio, TX, USA (D Sherman); Elkind 
Headache Center, Mount Vernon, NY, USA (A 
Elkind); Hôpital de la Pitié Salpêtrière, Paris, France (P 
Giral).
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